Skip to main content
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRVI ISIN · US89532M1018 US Manufacturing
Open in API
Filings indexed 505 across all filing types
Latest filing 2021-07-07 Capital/Financing Update
Country US United States of America
Listing US TRVI

About Trevi Therapeutics, Inc.

https://www.trevitherapeutics.com/

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of its investigational therapy, Haduvio™ (oral nalbuphine ER). The company's primary program is aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). These conditions represent a significant unmet medical need with no approved therapies in the United States. Haduvio is a dual-mechanism therapy that acts as a kappa opioid receptor agonist and a mu opioid receptor antagonist, targeting both central and peripheral nerve pathways believed to cause chronic cough. The company has reported positive results from its Phase 2b CORAL trial in IPF chronic cough and its Phase 2a RIVER trial in refractory chronic cough.

Recent filings

Filing Released Lang Actions
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It is a registration statement for the resale of shares by a selling stockholder, Lincoln Park Capital Fund, LLC, including details about the offering, the purchase agreement, and related disclosures. The document is not an annual report, earnings release, or any other financial report but rather a regulatory filing to register securities for resale. The presence of the SEC form type S-1 and the detailed registration and offering information clearly identifies this as a Capital/Financing Update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-07-07 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock incentive plans and employee stock purchase plans. It includes details about the securities to be registered, the plans under which they are offered, and signatures of company officers. This type of filing is related to share issuance and capital changes but is not a financial report, earnings release, or management discussion. It is specifically a registration statement for securities issuance under employee plans, which aligns with the category of Share Issue/Capital Change filings.
2021-07-06 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an amendment to a loan and security agreement with Silicon Valley Bank, detailing changes to financing terms and collateral requirements. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is primarily an update on a financing agreement, which fits the category of Capital/Financing Update (CAP). The document length is about 5293 characters, which is sufficient to contain substantive information about the financing amendment rather than just a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2021-07-06 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 16, 2021, reporting the submission of matters to a vote of security holders at the 2021 annual meeting. It details the election of directors and ratification of the independent auditor. The content focuses on voting results from the annual meeting, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3326 characters, which is relatively short but contains substantive voting results, not just an announcement of a report. Therefore, it is not a Report Publication Announcement (RPA). The document is not a full annual report, audit report, or management report, nor is it a proxy solicitation or other category. Hence, the best classification is DVA with high confidence.
2021-06-21 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 18, 2021, by Trevi Therapeutics, Inc. It details the entry into a material definitive agreement with Lincoln Park Capital Fund, LLC, specifically a purchase agreement for the sale of common stock and a registration rights agreement. The content focuses on financing activities, including terms of stock sales, commitment fees, and registration rights. There are no financial statements or comprehensive financial performance data included, nor is it an earnings release or annual/interim report. The document is clearly an update on capital raising and financing arrangements. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-06-21 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-17 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.